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Gastric emptyingThe intestinal hormone cholecystokinin (CCK) delays gastric emptying and inhibits food intake by actions
on vagal afferent neurons. Recent studies suggest plasminogen activator inhibitor (PAI)-1 suppresses the
effect of CCK on food intake. In this study we asked whether PAI-1 also modulated CCK effects on gastric
emptying. Five minute gastric emptying of liquid test meals was studied in conscious wild type mice
(C57BL/6) and in transgenic mice over-expressing PAI-1 in gastric parietal cells (PAI-1H/Kβ mice), or null
for PAI-1. The effects of exogenous PAI-1 and CCK8s on gastric emptying were studied after ip administra-
tion. Intragastric peptone delayed gastric emptying in C57BL/6 mice by a mechanism sensitive to the CCK-1
receptor antagonist lorglumide. Peptone did not delay gastric emptying in PAI-1-H/Kβ mice. Exogenous
CCK delayed gastric emptying of a control test meal in C57BL/6 mice and this was attenuated by administra-
tion of PAI-1; exogenous CCK had no effect on emptying in PAI-1-H/Kβmice. Prior administration of gastrin
to increase gastric PAI-1 inhibited CCK-dependent effects on gastric emptying in C57BL/6 mice but not in
PAI-1 null mice. Thus, both endogenous and exogenous PAI-1 inhibit the effects of CCK (whether exogenous
or endogenous) on gastric emptying. The data are compatible with emerging evidence that gastric PAI-1
modulates vagal effects of CCK.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
The delivery of liquid gastric contents to the duodenum is deter-
mined by their chemical composition. In particular, gastric emptying
is delayed by protein and fat content, osmolarity, viscosity and acid. A
number of different neuro-endocrine control mechanisms have been
identiﬁed that act either to change the pressure difference across the
pylorus, for example by relaxation of the gastric corpus, or by changing
the resistance to ﬂow across the pylorus. The role of the intestinal hor-
mone cholecystokinin (CCK) as a physiological regulator of the gastric
emptying of protein and fat has been relatively well studied since its
discovery in the mid-1970s [1–5].
Dietary protein and fatty acids with a chain length greater than
C12 release CCK which in turn regulates protein and lipid digestion
by stimulating delivery to the duodenum of bile salts (through
stimulation of gall bladder contraction) and pancreatic enzymes
(through stimulation of pancreatic acinar cell exocytosis) [6]. Atasminogen activator inhibitor.
Molecular Physiology, Institute
n St., Liverpool, L69 3BX, UK.
kray).
.V. Open access under CC BY license.the same time CCK inhibits gastric emptying and food intake thereby
matching delivery of food to the duodenum with the capacity for its
digestion. There is now considerable evidence that the latter actions
of CCK are mediated via stimulation of vagal afferent neurons which
express the CCK-1 receptor [7]. In particular, inhibition of gastric
emptying occurs through activation of vago-vagal reﬂexes leading
to relaxation of the gastric corpus, and perhaps also increased resis-
tance to ﬂow across the pylorus [2,3]. Recent work suggests a num-
ber of different mechanisms that modulate vagal responses to CCK,
including potentiation by leptin and inhibition by ghrelin [8–10].
Plasminogen activator inhibitor (PAI)-1 is normally expressed in
gastric parietal cells and ECL cells and there is evidence of increased
expression in response to high plasma gastrin concentrations [11]
and Helicobacter pylori infection [12,13]. In order to study the function
of PAI-1 in the stomach, we recently reported the generation of trans-
genic mice over-expressing PAI-1 in gastric parietal cells using a pro-
moter sequence of approximately 1 kb of the H/K-ATPase β-subunit.
Interestingly, these mice were moderately obese, hyperphagic and
insensitive to the satiety action of CCK; moreover experiments in rat
nodose ganglia in vitro indicated that the excitatory effect of CCK on
vagal afferent neurons was inhibited by PAI-1 [14]. On the basis of
these ﬁndings, we have now hypothesised that PAI-1 also inhibits the
effect of CCK on gastric emptying. We report here that PAI-1-H/Kβ
mice exhibit resistance to the effects of both endogenous and exoge-
nous CCK in delaying gastric emptying in mice.
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Fig. 1. Peptone delays gastric emptying in C57BL/6 mice but not in PAI-1-H/Kβ mice.
A, Peptone (5% w/v in 1.5% w/v methyl cellulose) inhibits gastric emptying compared
withmethyl cellulose alone in C57BL/6mice and the CCK-1 receptor antagonist, lorglumide
(4 mg/kg, ip) reverses this (n = 3–6; *, p b 0.05, ANOVA). B, Inhibition of gastric emptying
by peptone in C57BL/6 mice (n = 17; *, p b 0.05, t test) but not in PAI-1-H/Kβ mice
(n = 5). C, Pretreatment by gavage 5 min prior to test meals with the CCK-releasing
agent, camostat mesilate (FOY305, 100 mg/kg) signiﬁcantly delays gastric emptying of
methyl cellulose in C57BL/6 but not in PAI-1-H/Kβmice (n = 4–7; *p b 0.05, t test).
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2.1. Mice
Male mice, 10–13 weeks of age, were used for all studies. They
were maintained on a 12:12 h light/dark cycle. Transgenic mice on a
C57BL/6 background exhibiting targeted expression of PAI-1 in gastric
partial cells using 1.1 kb of the proximal promote of H+/K+ ATPase
β-subunit coupled to the coding sequence of mouse PAI-1 (i.e. PAI-1-H/
Kβ mice) have previously been described [14]. Wild type C57BL/6 mice
were obtained from Charles River (MA, USA) and mice null for PAI-1
were obtained from Jackson Laboratories (Maine, USA). All experiments
were approved by theUniversity of Liverpool AnimalWelfare Committee
and were conducted in compliance with the UK Animals (Scientiﬁc
Procedures) Act, 1986.
2.2. Materials
Methyl cellulose, meat peptone (Primatone) and phenol red
were obtained from Sigma-Aldridge (Gillingham, Dorset, UK);
camostat mesilate (FOY305), sulphated CCK octapeptide (CCK8s)
and unsulphated heptadecapeptide gastrin (G17ns) were obtained
from Tocris Biosciences (Bristol, UK). The CCK-1 receptor antago-
nist lorglumide was a kind gift from Dr Massimo D'Amato (Rotta
Research Laboratories, Milan, Italy). Stabilised human PAI-1 was
obtained from Calbiochem (Hertfordshire, UK) [15].
2.3. Gastric emptying
Micewere fasted overnight andwaterwas removed1 h prior to pro-
cedures. Animals received intraperitoneal injections (100 μl; CCK8s
or PAI-1 at 2.5 nmol/kg in saline, or saline alone) 5 min prior to gas-
tric emptying studies. In some experiments mice received gastrin
(20 nmol/kg) 6 h prior to gastric emptying studies. Mice received
liquid test meals of either methyl cellulose (1.5% w/v in distilled
water containing 50 mg/l phenol red) or peptone (4.5% w/v in methyl
cellulose solution) at a volume of 600 μl by gavage. In studies of
FOY305, animals were pretreated by gavage (100 μl, 100 mg/kg) 5 min
before the test meal. All test meals were pre-warmed to 37 °C. Mice
were culled 5 min after gavage by rising CO2 followed by cervical dislo-
cation. An abdominal incision was made, the pylorus and oesophageal
junctions were ligated, the stomach securely removed and the gastric
contents collected into Eppendorf tubes and centrifuged (12,000 rpm,
5 min). The supernatant was collected, the volume measured and sam-
ples alkalinisedwithNaOH and absorbance determined at 550 nm. Sam-
ples of methyl cellulose and peptone test meals were used as controls.
Gastric emptying was calculated as described by Debas et al. [1].
2.4. PAI-1 ELISA
Blood was obtained from fasted C57BL/6 mice, or PAI-1 null mice,
between 15.00 and 16.00 h via cardiac puncture, collected in 0.1 M
tri-sodium citrate, centrifuged and concentrations of plasma PAI-1
were determined by ELISA (Molecular Innovations, MI, USA) according
tomanufacturer's instructions. The assaywas validated bydemonstrating
(a) undetectable PAI-1 in plasma from PAI-1 null mice, and (b) parallel
dilution curves for standard PAI-1 and samples from C57BL/6 mice with
high endogenous PAI-1.
2.5. Statistics
Data are expressed as means ± S.E.; comparisons made by t test for
experiments involving a single experimental variable, or ANOVA for
multiple comparisons using Bonferroni correction, andwere considered
signiﬁcant at p b 0.05.3. Results
3.1. Peptone delays gastric emptying in C57BL/6 but not PAI-1-H/Kβmice
In initial experiments, we sought to adapt methods to the mouse
that had previously used to study the role of endogenous CCK on gas-
tric emptying in rats [3,16]. Thus over 85% of a control test meal of
methyl cellulose emptied in 5 min following intragastric administra-
tion. In contrast, peptone dissolved in the methyl cellulose solution
signiﬁcantly delayed gastric emptying compared with methyl cellu-
lose alone in C57BL/6 mice (Fig. 1A). The action of peptone was
reversed by prior administration of the CCK-1 receptor antagonist
lorglumide, consistent with a role for endogenous CCK in mediating
the action of peptone on gastric emptying in wild type mice
(Fig. 1A). However, in PAI-1-H/Kβ mice, peptone did not inhibit
11J. Gamble et al. / Regulatory Peptides 185 (2013) 9–13gastric emptying compared with methyl cellulose, and in fact emp-
tied slightly more rapidly (Fig. 1B). Moreover, a different type of
CCK-releasing meal, namely prior administration of FOY305 [17],
also signiﬁcantly delayed gastric emptying of methyl cellulose in
C57BL/6 mice but not PAI-1H/Kβ mice compatible with the conclu-
sion that over-expression of PAI-1 in gastric parietal cells inhibits
delayed gastric emptying by endogenous CCK (Fig. 1C).A
in 0.4
0.5
0.6 * * *
*3.2. PAI-1 attenuates the action of exogenous CCK on gastric emptying
To determine whether PAI-1-H/Kβmice were also resistant to the
effects of exogenous CCK, we then studied the action of ip CCK8s
(2.5 nmol/kg) on gastric emptying of a control test meal. At the
dose used, there was approximately 50% inhibition of emptying of
methyl cellulose in C57BL/6 mice. However, in PAI-1-H/Kβ mice
there was no signiﬁcant difference in the emptying of the control
test meal after CCK8s compared with ip saline (Fig. 2A). We then
asked whether exogenous PAI-1 also inhibited the effect of CCK on
gastric emptying. In C57BL/6 mice, the inhibition of emptying of
methyl cellulose in response to CCK8s was partially reversed by
prior administration of PAI-1 (2.5 nmol/kg) (Fig. 2B). Moreover,
ip administration of PAI-1 to C57BL/6 mice also accelerated the empty-
ing of a peptone test meal compatible with inhibition of endogenous
as well as exogenous CCK on gastric emptying (ip saline: 0.32 ±
0.02 ml of peptone emptied; ip PAI-1: 0.55 ± 0.02 ml emptied; t test,
p b 0.05).0
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Fig. 2. Exogenous CCK delays gastric emptying in C57BL/6 but not in PAI-1-H/Kβmice.
A, In C57BL/6, but not in PAI-1-H/Kβ, mice CCK8s (2.5 nmol/kg, 100 μl, ip) inhibits gas-
tric emptying of methyl cellulose (n = 4–5; *, p b 0.05, t test). B, The action of exoge-
nous CCK8s on gastric emptying in C57BL/6 mice is partially inhibited by exogenous
PAI-1 (2.5 nmol/kg, ip) (n = 5; *, p b 0.05, ANOVA).3.3. Increases in wild type PAI-1 reverse CCK-delayed gastric emptying
It is known that PAI-1 expression is highly regulated, and elevat-
ed plasma gastrin is associated with increased expression in gastric
epithelial cells notably parietal cells and ECL cells [11]. We therefore
asked whether prior administration of gastrin to increase gastric
PAI-1 might modulate CCK-effects on gastric emptying. There was
increased plasma PAI-1 in C57BL/6 mice 6 h following ip administra-
tion of G17ns (20 nmol/kg) compared with saline (ip saline: 4.6 ±
0.6 ng/ml; G17ns: 9.8 ± 1.0 ng/ml; t test, p b 0.05); there was no
signiﬁcant difference in plasma PAI-1 after acute administration of
CCK. In C57BL/6 mice, prior administration of G17ns signiﬁcantly re-
versed the effect of subsequent administration of CCK8s in delaying
emptying of methyl cellulose (Fig. 3A). Strikingly, however, in
PAI-1 null mice, CCK inhibition of gastric emptying was maintained
after prior treatment with G17 indicating a role for endogenous
PAI-1 in mediating the effect of gastrin (Fig. 3B).B
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Fig. 3. Pretreatmentwith gastrin (G17ns) reverses the effect of CCKongastric emptying in
C57BL/6 mice but not in PAI-1−/−mice. A, Pretreatment with G17ns (20 nmol/kg, ip, 6 h
previously), which signiﬁcantly increases plasma PAI-1, inhibits the effect of CCK8s
(2.5 nmol/kg, ip) on gastric emptying of methyl cellulose in C57BL/6 mice (n = 6;
*, p b 0.05, ANOVA). B, Pretreatment with G17ns has no effect on the inhibition of gastric
emptying of methyl cellulose in response to CCK8s in PAI-1−/− mice (n = 6; *, p b 0.05
ANOVA).
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The main ﬁnding of this study is that PAI-1 suppresses the inhibi-
tion of gastric emptying by CCK inmice. It is well recognised that CCK
stimulates vagal afferent neurons resulting in delayed nutrient deliv-
ery to the small intestine by inhibition of both gastric emptying and
food intake [7]. Previous studies have shown that PAI-1 suppresses
CCK-inhibition of food intake, and have provided evidence that it
also inhibits CCK-stimulation of vagal afferent neurons [14]. The
present study was therefore undertaken to examine the hypothesis
that PAI-1 also suppressed CCK inhibition of gastric emptying. The
data derived from studies in transgenic mice over-expressing PAI-1
in the stomach, in PAI-1 null mice, and in wild type mice receiving
exogenous CCK or PAI-1, all indicate that PAI-1 (whether exogenous
or endogenous) inhibits the effect of CCK (both endogenous and
exogenous) on gastric emptying. Thus PAI-1 should now be considered
a putative modulator of CCK effects on gastric emptying in health and
disease.
There is widespread expression of PAI-1 in many different cells
including platelets, endothelial cells, hepatocytes, macrophages,
monocytes, adipocytes and adipose stromal cells. Expression is in-
creased in response to inﬂammation, sepsis, TGFβ and plasma con-
centrations are elevated in obesity [18–20]. In the stomach, there is
expression of PAI-1 in both epithelial and stromal cells, and in-
creased expression in parietal and ECL cells has been reported in re-
sponse to gastrin [11] and H. pylori [12,13]. In PAI-1-H/Kβ mice
targeted expression of PAI-1 to parietal cells was achieved using a
promoter sequence of approximately 1 kb of the H/K-ATPase
β-subunit which has been well characterised for this purpose. In
qPCR, primers speciﬁc for the transgene sequence conﬁrm selective
expression in the stomach, while qPCR primers measuring total tis-
sue PAI-1 mRNA abundance (i.e. transgene plus wild-type product)
indicated an approximately 3-fold increase in gastric mRNA abun-
dance. These animals exhibit approximately 25% higher food intake
and moderate life-long obesity; moreover the hyperphagia in these
animals is at least partly a consequence of insensitivity to CCK [14].
The increase in gastric PAI-1 mRNA abundance in PAI-1-H/Kβ mice
is comparable to the changes seen in hypergastrinaemia, so that
the insensitivity exhibited by these mice to CCK is presumably func-
tionally meaningful.
One of the major actions of PAI-1 is inhibition of the tissue and uro-
kinase plasminogen activators (tPA, uPA) that convert plasminogen to
plasminwhich in turn digestsﬁbrin, so that PAI-1 is an important player
in ﬁbrinolysis. In addition, PAI-1 binds vitronectin, and disrupts interac-
tions with αvβ3 integrins and the uPA receptor (uPAR) leading to bio-
logical properties that are independent of tPA or uPA [20]. Previously,
uPARwas shown to be expressed by vagal afferent neurons, and knock-
down of uPAR expression was associated with decreased capacity of
PAI-1 to inhibit CCK effects in vitro and in vivo [14]. In PAI-1H/Kβmice
there are relatively small changes in plasma PAI-1 compared with
C57BL/6 mice, and although not examined directly in the present
study, it seems reasonable to suppose that PAI-1 released from gastric
epithelial cells in thesemice acts locally at uPAR on vagal afferent ﬁbres
to decrease sensitivity to CCK in inhibiting gastric emptying.
In obesity, there is evidence for attenuation of the action of CCK in
inhibiting gastric emptying [21,22]. Various mechanisms have been
discussed including changes in the sensitivity of vagal afferent neurons
to CCK with possible roles for the microbiota, interactions with other
factors including leptin and ghrelin and neurochemical changes in re-
ceptor and neuropeptide gene expression [23–27]. Since there is in-
creased plasma PAI-1 in obesity [18,28] it seems possible that this
may also account for depression of responses to CCK. The different pro-
posedmechanismsmay not, of course, bemutually exclusive and future
work will beneﬁt from systematic dose–response studies. Moreover, in
this context it is worth noting that there are multiple populations of
vagal afferent neurons that respond to CCK and the precise populationsmediating effects on food intake and on gastric emptying remain
incompletely characterised [29]. Thus while the neuronal popula-
tions targeted by PAI-1 remain to be identiﬁed this should be
seen in the context of a wider need for the functional characterisa-
tion of sub-diaphragmatic vagal afferent neurons.
Multiple gut signals regulate gastric emptying including inhibitory
roles for several gut hormones in addition to CCK, e.g. GLP-1 and
PYY3-36 as well the lipid amide oleylethanolamide, and stimulatory
roles for regulatory peptides such as ghrelin [30]. The inhibitory action
of PAI-1 against CCK does not preclude interactions with other media-
tors that could be studied in the future. It is notable that intestinal
PAI-1may be increased after radiation damage [31], in experimental co-
litis [32], and in intestinal neurons in Crohn's disease [33]. Given that
some effects of endogenous CCK on stomach function appear to be me-
diated by paracrine actions on intestinal vagal afferent ﬁbres while
others are mediated by actions of circulating CCK on gastric vagal affer-
entﬁbres [29], it would not be surprising if intestinal PAI-1 also played a
role in modulating gastric emptying by acting locally on vagal afferent
nerve ﬁbres. In some of the circumstances that are associated with in-
creased PAI-1 there are also increases in proinﬂammatory mediators
such as IL1β that enhance vagal responses to CCK [34,35]. The present
data therefore suggest a role for gastric PAI-1 in maintaining nutrient
delivery to the small intestine in health and disease by counteracting in-
teractions at vagal afferent neurons between CCK and factors that en-
hance its effects.Acknowledgements
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